📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-05 18:13
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
29 announcements match the current filters (relevance ≥ 5).
Metropolis Reports ~15% YoY Revenue Growth for Q2FY27 with Margin Expansion
Metropolis Healthcare released its Q2FY27 business update reporting consolidated revenue growth of approximately 15% YoY. The performance was anchored by double-digit patient and test volume growth alongside improved realizations and a favorable product mix. TruHealth Wellness and Specialty segments were the fastest-growing categories during the quarter. Furthermore, EBITDA margins improved meaningfully on both a YoY and QoQ basis due to operating leverage and operational efficiencies.
Confidence: HIGH
What changedMetropolis shared preliminary operating trends for Q2FY27 ahead of full audited financial results.
Why it mattersA 15% YoY revenue growth paired with margin expansion indicates sustained demand and operating leverage, following a base of Rs 429.2 Cr revenue in Q2FY26 (Sep 2025).
YoY Revenue Growth: ~15%Volume Growth: double digitPrevious Year Q2 Revenue (Sep 2025): Rs 429.19 Cr
📅 Short termPositive sentiment likely in the near term as volume growth returns to double digits with sequential and yearly margin expansion.
📈 Long termExpansion in high-margin TruHealth wellness and specialty segments supports Metropolis's 3.0 strategy and structural margin resilience.
⚠ Risk flags
- Final audited figures and exact EBITDA margins are yet to be approved by the Board
Key Highlights
Consolidated revenue grew by approximately 15% YoY in Q2FY27
Growth led by double-digit patient and test volume expansion
TruHealth Wellness and Specialty segments emerged as fastest-growing segments
EBITDA margins improved meaningfully on both YoY and QoQ basis
👀 What to Watch
Track the detailed Q2FY27 financial results and investor presentation for exact margin expansion numbers, realization per patient, and full audited figures.
Metropolis Guides 14–15% FY27 Growth, Targets 27–28% EBITDA Margin Over 3 Years
Metropolis Healthcare presented its 3-year strategic roadmap at its Analyst Meet, reaffirming an FY27 revenue growth guidance of 14–15% with a 100–150 bps margin improvement after delivering ₹450 Cr revenue (+17% YoY) in Q1 FY27. Over the next three years, the company aims to expand EBITDA margins from 24.4% to 27–28%, driven by network density, specialty test mix (aiming for 45% of revenue), and the turnaround of Core Diagnostics (targeting 20%+ margin by Year 3). Capex is guided to remain asset-light at ~4% of revenue, supporting balance sheet efficiency and ROCE expansion.
Confidence: HIGH
What changedMetropolis released its 2026 Analyst Meet presentation detailing 3-year targets, volume-led growth expectations, and margin expansion levers.
Why it mattersProvides visibility into management's mid-term targets, highlighting disciplined capital allocation (capex ~4% of revenue) and margin accretion via specialty diagnostics and M&A integration.
FY27 revenue growth guidance: 14–15%Q1 FY27 revenue: ₹450 Cr3-Year EBITDA margin target: 27–28%Annual capex guidance: 4% of revenueOwn centre target: 1,000 stores
📅 Short termInformational presentation; provides clarity on full-year targets and confirms positive operating momentum seen in Q1 FY27.
📈 Long termExecution on expanding the centre-to-lab ratio to 35:1 and turning around Core Diagnostics could structurally support operating margins and ROCE compounding.
⚠ Risk flags
- Execution risk on turnaround of acquired assets (Core Diagnostics) to reach 20%+ margin
- Intense competitive pricing pressure from regional and digital diagnostic aggregators
Key Highlights
FY27 revenue growth guided at 14–15% with +100–150 bps EBITDA margin expansion; Q1 FY27 delivered ₹450 Cr revenue (+17% YoY) at 25.2% margin
3-year target to expand EBITDA margin to 27–28% (from 24.4% in FY26) through operating leverage and Core Diagnostics turnaround
Network expansion roadmap to scale own centres from ~750 to 1,000, lifting centre-to-lab ratio from 24:1 to ~35:1
Specialty testing mix targeted to reach 45% of revenue (up from 40% in Q1 FY27), with capex contained at ~4% of revenue
👀 What to Watch
Track quarterly revenue trajectory against the 14–15% annual guidance and monitor progress on EBITDA margin expansion toward the 27–28% target in upcoming quarters.
17% Q1 Revenue Growth; Metropolis Targets 27-28% EBITDA Margin in 2 Years
Metropolis Healthcare reported a strong Q1 FY27 with ~17% YoY revenue growth, exceeding its previous guidance. Management has maintained a full-year revenue growth outlook of 14-15%, primarily driven by volume growth in Tier-2 and Tier-3 markets. A key focus is margin expansion, with a targeted 100-150 bps improvement in EBITDA for FY27 and a long-term goal of 27-28%. The integration of Core Diagnostics is progressing, with margins currently at ~8% and a target of 25% within 3-4 years.
Confidence: HIGH
What changedMetropolis has shifted from an integration phase to a margin-expansion phase, backed by a Q1 revenue beat and specific margin improvement targets.
Why it mattersThe diagnostic industry is seeing a shift toward organized players; Metropolis's ability to expand margins while growing volumes by 14-15% is critical for valuation re-rating.
Q1 Revenue Growth (YoY): 17%FY27 Revenue Guidance: 14-15%Target EBITDA Margin: 27-28%Core Diagnostics Margin: 8%TruHealth Ticket Size: ₹2,500Planned Center Additions: 500
📅 Short termPositive sentiment expected as the company exceeded revenue guidance and provided a clear roadmap for margin recovery.
📈 Long termStructural growth in specialty diagnostics (2,200+ tests) and expansion into 800 towns support long-term volume-led growth.
⚠ Risk flags
- Intensifying competition from health-tech platforms could pressure pricing by 5-10%
- Execution risk in scaling Core Diagnostics margins from 8% to 25%
Key Highlights
Revenue grew by approximately 17% year-on-year in Q1 FY27, exceeding management's stated guidance.
Management targets 100-150 bps EBITDA margin expansion in FY27, aiming for a 27-28% margin over the next two years.
Core Diagnostics acquisition currently operates at a high single-digit margin (~8%), with a target to reach 25% in 3-4 years.
TruHealth business vertical maintains a ticket size of approximately ₹2,500 with margins in line with company averages.
Company plans a net addition of 500 centers during the year to improve the center-to-lab ratio towards 30:1.
👀 What to Watch
Monitor the volume growth trajectory in Tier-2/3 cities and the quarterly progression of EBITDA margins toward the 27-28% target to validate operating leverage claims.
17% Revenue Growth to ₹450 Cr: Metropolis Reports Strong Q1FY27 Performance
Metropolis Healthcare reported a strong start to FY27 with revenue growing 16.6% YoY to ₹450.2 crore, driven by a 10% increase in patient volumes. Profitability improved significantly as EBITDA rose 27.1% YoY to ₹113.2 crore, resulting in a 210 bps margin expansion to 25.2%. The growth was broad-based, with B2C revenue up 18% and Tier III cities growing at 25% YoY. PAT increased by 25.8% to ₹56.9 crore, reflecting strong operating leverage and a richer test mix.
Confidence: HIGH
What changedMetropolis reported its Q1FY27 financial results, showing double-digit growth in revenue and profit with significant margin improvement compared to the previous year.
Why it mattersThe results demonstrate the company's ability to drive volume-led growth and margin expansion without price hikes, highlighting brand strength and operational efficiency despite intensifying competition in the diagnostic sector.
Revenue (Q1FY27): ₹450.2 crEBITDA Margin: 25.2%PAT Growth (YoY): 25.8%Revenue vs TTM Revenue: ~27.3%TruHealth Revenue: ₹81 cr
📅 Short termThe stock may see positive sentiment in the coming days as the 25.2% EBITDA margin exceeds the TTM OPM of 24.4%, indicating improved operational efficiency.
📈 Long termStructural growth remains tied to deeper penetration in Tier III towns and the shift of market share from unorganized to organized players through the Metropolis 3.0 strategy.
⚠ Risk flags
- Intensifying competition from large conglomerates and health-tech platforms
- Potential pricing pressure in the wellness segment
- Integration risks of bolt-on acquisitions
Key Highlights
Revenue from operations increased 16.6% YoY to ₹450.2 crore for Q1FY27.
EBITDA margins expanded by 210 basis points to reach 25.2%, up from 23.1% YoY.
Wellness segment (TruHealth) revenue grew 22% YoY to ₹81 crore, now 18% of segment mix.
Tier III cities were the fastest-growing markets with ~25% YoY revenue growth.
Patient volume and test volume grew by 10% and 11% YoY respectively without price increases.
👀 What to Watch
Investors should monitor the sustainability of volume-led growth in Tier III markets and the execution of the 'Metropolis 3.0' strategy, particularly the integration of acquisitions like Core Diagnostics.
17% Revenue Growth and 27% EBITDA Growth in Q1 FY27; Margins Expand to 25.2%
Metropolis Healthcare reported a strong Q1 FY27 with revenue reaching INR 450.2 Cr, a 17% YoY increase driven by volume growth rather than price hikes. EBITDA grew 27% YoY to INR 113.2 Cr, with margins expanding by 210 bps to 25.2% due to operating leverage and automation. Patient volumes rose 10% to 3.7 million, while the high-margin TruHealth (wellness) segment grew 22%. The company is successfully executing its 'Metropolis 3.0' strategy, with Tier-3 city revenue growing significantly by 25% YoY.
Confidence: HIGH
What changedMetropolis has shifted to a volume-led growth model (10% patient growth) without relying on price hikes, while simultaneously expanding margins through automation and network rationalization.
Why it mattersThe results demonstrate strong execution of the 'Metropolis 3.0' strategy, proving the company can scale in fragmented markets (Tier-3) and high-margin segments (Wellness/Specialty) despite intense industry competition.
Q1 Revenue: INR 450.2 CrQ1 Revenue vs TTM Revenue: 27.3%EBITDA Margin: 25.2%Patient Volume Growth: 10% YoYService Network: 5,003 points
📅 Short termThe stock may see positive momentum in the coming weeks as the market reacts to the margin expansion and robust volume-led revenue growth that outperformed previous guidance.
📈 Long termThe structural shift toward organized diagnostic chains and the company's expansion into Genomics and Radiology provide a clear path for sustained double-digit growth over the next 3-5 years.
⚠ Risk flags
- Intensifying competition from large conglomerates and health-tech platforms
- Geographic concentration with 50% revenue still coming from West India
- Potential 5-10% pricing pressure in routine testing
Key Highlights
Revenue from operations increased 16.6% YoY to INR 450.2 Cr in Q1 FY27
EBITDA margins expanded by 210 bps YoY to reach 25.2%
Patient volume grew by 10% YoY to 3.7 million, while test volume rose 11% to 7.8 million
Tier-3 city revenue grew by 25% YoY, now contributing 26% of total revenue
Wellness segment (TruHealth) revenue increased 22% YoY to INR 81 Cr
👀 What to Watch
Watch for the sustainability of double-digit volume growth in Tier-3 markets and the impact of competitive pricing from health-tech platforms on long-term margins. Monitor the integration of the Core Diagnostics menu and its contribution to specialty testing revenue.
Metropolis Q1 FY27: Net Profit Rises 42% YoY to ₹50.6 Cr; Revenue Up 15%
Metropolis Healthcare reported a strong performance for Q1 FY27, with consolidated revenue growing 15.2% YoY to ₹372.3 Cr. Net profit surged 42.2% YoY to ₹50.6 Cr, significantly outpacing revenue growth and indicating improved operating leverage. On a sequential basis, revenue grew 5.8% compared to the March 2026 quarter. The company also noted a two-month delay in the internal transfer of its Quality Assessment business to a wholly-owned subsidiary.
Confidence: HIGH
What changedThe company reported its first-quarter results for FY27, showing double-digit growth in revenue and a substantial jump in profitability compared to the same period last year.
Why it mattersThe results demonstrate strong pricing power and operational efficiency in a competitive diagnostic market. The profit growth outperforming revenue growth suggests that the company is successfully managing its cost base while scaling volumes.
Revenue (Q1 FY27): ₹372.28 CrNet Profit (Q1 FY27): ₹50.58 CrYoY Revenue Growth: 15.2%YoY Net Profit Growth: 42.2%ESOPs Granted: 2,12,345 units
📅 Short termThe stock is likely to react positively in the short term due to the significant earnings beat and margin expansion compared to the previous year.
📈 Long termThe company's focus on specialized segments like Genomics and Radiology, combined with its 'T3 Acceleration' strategy, supports a structural growth outlook for the organized diagnostic sector.
⚠ Risk flags
- Intensifying competition from health-tech platforms and large conglomerates
- Delay in internal business restructuring (Quality Assessment business transfer)
Key Highlights
Revenue from operations increased 15.2% YoY to ₹372.28 Cr from ₹323.27 Cr in the previous year.
Net Profit after tax grew 42.2% YoY to ₹50.58 Cr, up from ₹35.58 Cr in Q1 FY26.
Profit Before Tax (PBT) stood at ₹66.38 Cr, representing a 40% increase over the ₹47.38 Cr reported in the same quarter last year.
The company granted 2,12,345 ESOPs and 14,236 RSUs to eligible employees during the quarter.
The transfer of the External Quality Assessment Services business is now expected to take an additional 2 months beyond the original August 2026 deadline.
👀 What to Watch
Investors should monitor if the high profit growth rate is sustainable through the high-volume Q2 period. Watch for updates on the integration of recent acquisitions and the execution of the 'Metropolis 3.0' strategy in the Top 800 towns.
16% YoY Revenue Growth in Q1FY27; Wellness and Specialty Segments Lead Performance
Metropolis Healthcare reported a healthy ~16% YoY revenue growth for Q1FY27, primarily driven by increased patient volumes and improved realizations from a better product mix. The TruHealth Wellness and Specialty segments were the fastest-growing areas during the quarter. EBITDA margins improved on a year-on-year basis, meeting management guidance, while remaining stable compared to the previous quarter (Q4FY26). Both B2C and B2B segments showed volume growth, supported by network expansion and higher wallet share from existing customers.
Confidence: HIGH
What changedThis filing provides a preliminary business update for Q1FY27, indicating double-digit revenue growth and margin improvement ahead of the formal earnings release.
Why it mattersThe 16% growth suggests that Metropolis is successfully navigating competitive pressures from health-tech platforms while shifting its mix toward higher-margin wellness and specialty testing.
Revenue Growth (YoY): ~16%TTM Revenue: Rs 1646 CrOperating Profit Margin (TTM): 24.4%Market Cap: Rs 3582 Cr
📅 Short termThe stock may see positive sentiment in the coming days as the 16% growth rate and margin improvement signal a strong start to the new fiscal year.
📈 Long termThe focus on 'Metropolis 3.0' and expansion into high-science domains like Genomics and Wellness is structurally positive for long-term realizations and market share.
⚠ Risk flags
- Intensifying competition from large conglomerates and health-tech platforms
- Potential pricing pressure of 5-10% in the diagnostic industry
Key Highlights
Consolidated revenue grew by approximately 16% on a Y-o-Y basis for the quarter ended June 30, 2026.
EBITDA margins improved year-on-year, aligning with the company's previous guidance.
TruHealth Wellness and Specialty segments emerged as the fastest-growing business units.
B2C growth was supported by increased throughput across the expanded center network.
👀 What to Watch
Investors should wait for the detailed Q1FY27 financial results to confirm the exact EBITDA margin expansion and assess the impact of the Core Diagnostics acquisition on the bottom line.
Metropolis FY26 Organic Revenue Up 13.7%; Targets 27-28% EBITDA Margin in 3 Years
Metropolis Healthcare reported a strong FY26 with organic revenue growth of 13.7%, exceeding its guidance of 12-13%. The company successfully integrated Core Diagnostics, turning its EBITDA from -2% to high-single digits in Q4 FY26. Management has provided a robust 3-year outlook targeting a revenue CAGR of 14-15% and group EBITDA margins of 27-28%. Additionally, the board recommended an interim dividend of INR 1 per share, following a bonus issue in March 2026.
Key Highlights
Organic revenue grew 13.7% in FY26, with normalized organic margins expanding 140 bps to 25.9%.
Core Diagnostics integration achieved high-single-digit EBITDA in Q4, on track for 20% plus target in 3 years.
North India revenue contribution increased to 17%, while digital channels now account for 25% of total revenue.
Expansion plan includes adding 1,500 collection centers and 100 mini hubs (pathology + radiology) over 3 years.
B2C segment remains strong at 60% of total revenue with self-referrals contributing 40%.
👀 What to Watch
Investors should take confidence in the margin expansion and the successful turnaround of Core Diagnostics. The clear 3-year growth roadmap and focus on high-margin specialty genomics make it a strong candidate for long-term portfolios.
Metropolis Healthcare Corrects FY25 Comparative Profit Figures; FY26 Standalone PAT at ₹157.5 Cr
Metropolis Healthcare issued a correction to its May 13, 2026, financial results filing due to an inadvertent error in the comparative profit figures for the quarter ended March 31, 2025. The company clarified that this administrative correction is non-material and has no impact on the current financial year's performance. For the full year FY26, the company reported a standalone revenue of ₹1,365.5 crore, a 12.3% increase over FY25. Standalone net profit for FY26 rose to ₹157.5 crore, up from ₹124.8 crore in the previous fiscal year.
Key Highlights
FY26 Standalone Revenue grew 12.3% YoY to ₹1,36,547.17 Lakhs.
Standalone Net Profit for FY26 increased to ₹15,748.33 Lakhs from ₹12,479.60 Lakhs in FY25.
Q4 FY26 Standalone Revenue stood at ₹35,203.12 Lakhs compared to ₹31,168.61 Lakhs in Q4 FY25.
The administrative correction pertains only to the comparative Q4 FY25 profit figure and does not affect FY26 results.
Basic EPS for FY26 improved to ₹7.60 from ₹6.01 in the previous year.
👀 What to Watch
Investors should focus on the healthy 12.3% revenue growth and significant profit expansion in FY26, as the reported correction is purely administrative and pertains to historical data. The underlying business performance remains robust with improving margins.
Metropolis Q4FY26: PAT jumps 75% YoY to ₹51 Cr, EBITDA up 71%; ₹1 Dividend declared
Metropolis Healthcare reported a strong Q4FY26 with revenue growing 23% YoY to ₹425 Cr, driven by an 11% increase in patient volumes. Profitability saw a significant boost with PAT rising 75% YoY to ₹51 Cr and EBITDA margins expanding to 25.4% from 18.5% in the previous year. The company successfully crossed the 5,000-center milestone and saw robust growth in both B2C (20%) and B2B (28%) segments. Additionally, the board has recommended a dividend of ₹1 per share.
Key Highlights
Revenue grew 23% YoY to ₹425 Cr, while PAT surged 75% YoY to ₹51 Cr.
EBITDA increased by 71% YoY to ₹108 Cr with margins expanding to 25.4% from 18.5%.
Patient volumes and test volumes grew by 11% and 14% YoY, respectively.
B2B revenues showed strong growth of 28% YoY, while B2C revenues grew by 20%.
The company reached a milestone of 5,000+ centers and declared a ₹1 dividend per share.
👀 What to Watch
The significant margin expansion and double-digit volume growth suggest strong operational leverage and market share gains. Investors should maintain a positive outlook while watching for the sustainability of these high margins in a competitive diagnostic landscape.
Metropolis Q4 FY26: PAT Surges 75% to ₹51 Cr; Group Revenue Grows 23% YoY to ₹425 Cr
Metropolis Healthcare reported a robust performance for Q4 FY26, with group revenue rising 23% YoY to ₹425 Cr and PAT increasing 75% to ₹51 Cr. The organic business showed strong momentum with a 15% revenue growth and EBITDA margins expanding to 27.2% in Q4. Growth was driven by a 9.3% increase in organic patient volumes and a 5% rise in revenue per patient. The company successfully integrated three acquisitions during the year, which contributed 8% to the total FY26 revenue.
Key Highlights
Group PAT for FY26 grew 31% YoY to ₹191 Cr on a total revenue of ₹1,646 Cr
Organic EBITDA margins improved significantly to 27.2% in Q4 FY26 from 18.5% in Q4 FY25
TruHealth (wellness) and Specialty segments grew by 21% and 16% respectively in FY26 (Organic)
B2C revenue grew 14% YoY in FY26, supported by deeper penetration into Tier 3 markets
Acquisitions of DAPIC, Scientific Pathology, and Ambika are fully integrated; Core Diagnostics integration expected by Q1FY27
👀 What to Watch
Investors should view the strong margin expansion and volume-led growth as a sign of high operating leverage. The successful integration of acquisitions and the shift towards high-margin specialty and wellness tests suggest a sustainable growth trajectory.
Metropolis Healthcare FY26 Net Profit Rises 26% to ₹157 Cr; Declares ₹1 Dividend
Metropolis Healthcare reported a robust performance for FY26, with standalone revenue growing 12.3% YoY to ₹1,365.5 crore and net profit increasing by 26.4% to ₹157.1 crore. The company declared a second interim dividend of ₹1 per share, reflecting a payout on a face value of ₹2. Significant corporate changes include the transition of Dr. Nilesh Shah from President to an advisory role and the appointment of Deloitte Haskins & Sells as the new statutory auditors for a five-year term.
Key Highlights
Standalone Revenue for FY26 increased to ₹1,365.5 crore from ₹1,215.8 crore in the previous year
Net Profit for the full year grew by 26.4% YoY, reaching ₹157.1 crore compared to ₹124.3 crore
Declared a 2nd interim dividend of ₹1 per equity share with a record date of May 19, 2026
Dr. Nilesh Shah transitions from President - Internal Assurance to an advisory role effective May 14, 2026
Deloitte Haskins & Sells appointed as new Statutory Auditors for 5 years, replacing B S R & Co. LLP
👀 What to Watch
Investors should take note of the strong double-digit profit growth and consistent dividend payouts as signs of operational efficiency. The transition of a senior leader to an advisory role and the change in auditors are routine but should be monitored for any shifts in internal governance.
Metropolis FY26 Profit Jumps to ₹157 Cr; Declares ₹1 Dividend & Appoints Deloitte as Auditor
Metropolis Healthcare reported a strong financial performance for FY26, with standalone net profit rising to ₹157.14 crore from ₹124.34 crore in the previous year. The company declared a second interim dividend of ₹1 per share, setting May 19, 2026, as the record date. In a significant governance move, the board has recommended Deloitte Haskins & Sells as the new statutory auditors for a five-year term, replacing the retiring B S R & Co. LLP. Additionally, the company announced the transition of Dr. Nilesh Shah from a senior management role to an advisory position.
Key Highlights
Standalone Revenue from operations increased to ₹1,365.47 crore in FY26, up from ₹1,215.75 crore in FY25.
Standalone Net Profit for the full year grew by approximately 26.4% year-on-year to ₹157.14 crore.
Declared a 2nd Interim Dividend of ₹1 per equity share (50% of face value) for FY25-26.
Deloitte Haskins & Sells Chartered Accountants LLP recommended as new Statutory Auditors for 5 consecutive years.
Dr. Nilesh Shah, President - Internal Assurance, transitions to an advisory role effective May 14, 2026.
👀 What to Watch
Investors should take note of the robust double-digit profit growth and the transition to a Big Four auditor, which reinforces corporate governance. The stock remains attractive for dividend seekers with the upcoming record date of May 19.
Metropolis Healthcare FY26 Profit Jumps 26% to ₹157 Cr; Declares ₹1 Interim Dividend
Metropolis Healthcare reported a robust financial performance for FY26, with consolidated revenue reaching ₹1,365.47 crore, a 12.3% increase year-on-year. Net profit for the full year grew by approximately 26% to ₹157.14 crore, driven by strong operational performance in the final quarter. The company announced a second interim dividend of ₹1 per share, setting May 19, 2026, as the record date. Strategic changes include the appointment of Deloitte as the new statutory auditor and a transition in senior management.
Key Highlights
Annual revenue from operations grew 12.3% YoY to ₹1,36,547.17 Lakhs in FY26.
Q4 FY26 net profit from continuing operations rose to ₹4,326.07 Lakhs from ₹2,368.59 Lakhs YoY.
Declared 2nd interim dividend of ₹1 per share (50% of face value) with record date of May 19, 2026.
Proposed Deloitte Haskins & Sells as new Statutory Auditors for a 5-year term starting from the 26th AGM.
Dr. Nilesh Shah, President - Internal Assurance, transitions to an advisory role effective May 14, 2026.
👀 What to Watch
The strong earnings growth and dividend declaration reflect healthy cash flows and a solid market position; investors may consider holding or accumulating on dips. Monitor the auditor transition to ensure continued transparency in financial reporting.
Metropolis FY26 Net Profit Rises 26% to ₹157.14 Cr; Declares ₹1 Interim Dividend
Metropolis Healthcare reported a strong financial performance for FY26, with standalone revenue from operations reaching ₹1,365.47 crore, a 12.3% increase over the previous year. Net profit from continuing operations grew by 26.4% to ₹157.14 crore compared to ₹124.34 crore in FY25. The board has declared a second interim dividend of ₹1 per share (50% of face value) with a record date of May 19, 2026. Additionally, the company is transitioning its statutory auditors to Deloitte Haskins & Sells following the completion of B S R & Co. LLP's term.
Key Highlights
Standalone Revenue from operations grew 12.3% YoY to ₹1,365.47 crore for the full year FY26.
Net Profit from continuing operations increased by 26.4% YoY to ₹157.14 crore.
Declared 2nd Interim Dividend of ₹1 per equity share with a Record Date of May 19, 2026.
Q4 FY26 revenue stood at ₹352.03 crore, up from ₹311.69 crore in the same quarter last year.
Proposed appointment of Deloitte Haskins & Sells as new Statutory Auditors for a 5-year term.
👀 What to Watch
Investors should take note of the healthy double-digit growth in both top-line and bottom-line figures, which indicates strong operational execution. The dividend declaration and the appointment of a Big 4 audit firm (Deloitte) further reinforce corporate governance and shareholder returns.
Metropolis Healthcare FY26 Profit Rises 26% to ₹157 Cr; Declares ₹1 Interim Dividend
Metropolis Healthcare reported a strong financial performance for the year ended March 31, 2026, with annual revenue from operations growing 12.3% to ₹1,365.47 crore. Net profit from continuing operations saw a robust increase of 26.4% YoY, reaching ₹157.14 crore. The company declared a second interim dividend of ₹1 per share and announced the appointment of Deloitte Haskins & Sells as the new statutory auditors, replacing B S R & Co. LLP upon completion of their term.
Key Highlights
Annual Revenue from operations increased 12.3% YoY to ₹1,36,547.17 Lakhs.
Standalone Profit After Tax for Q4 FY26 surged 82.6% YoY to ₹4,326.07 Lakhs.
Declared 2nd interim dividend of ₹1 per equity share (50% of face value) with a record date of May 19, 2026.
Full-year Profit After Tax from continuing operations grew 26.4% to ₹15,714.10 Lakhs.
Transitioned Dr. Nilesh Shah from President - Internal Assurance to an advisory role effective May 14, 2026.
👀 What to Watch
Investors should take note of the significant margin improvement and strong bottom-line growth in Q4. The consistent dividend payout and appointment of a Big 4 auditor (Deloitte) further strengthen investor confidence in corporate governance and cash flow stability.
Metropolis Healthcare Q4FY26 Revenue Jumps 23% YoY, Organic Growth at 14.5%
Metropolis Healthcare reported a strong consolidated revenue growth of approximately 23% YoY for Q4FY26, driven by wellness and specialized testing. Organic revenue, excluding recent acquisitions, grew by 14.5% due to increased patient volumes and improved product mix. The B2B segment significantly outperformed with 30% growth, while B2C grew by 19%. Management noted improved EBITDA margins and successful integration of recent acquisitions like Core Diagnostics and DAPIC.
Key Highlights
Consolidated revenue grew by ~23% YoY, while organic revenue rose by ~14.5% YoY.
B2B revenue segment grew by ~30% YoY, outpacing B2C growth of ~19% YoY.
TruHealth Wellness and Specialty segments recorded robust growth of ~25% and ~29% respectively.
EBITDA margins improved YoY driven by operating leverage and efficiency gains.
Core Diagnostics margins reached high single-digits, with other acquisitions delivering above-average margins.
👀 What to Watch
Investors should maintain a positive outlook as the company shows strong volume-led organic growth and successful inorganic integration. Watch for the full audited results to confirm the exact margin expansion and sustainability of the B2B growth momentum.
Metropolis Healthcare Allots 15.55 Crore Bonus Shares in 3:1 Ratio
Metropolis Healthcare has officially allotted 15,54,95,826 equity shares as part of its 3:1 bonus issue. Shareholders as of the record date, March 20, 2026, have been issued three new fully paid-up shares for every one share held. This corporate action has increased the company's total paid-up share capital to INR 41.47 crore. The total number of equity shares in the company now stands at 20,73,27,768, significantly enhancing the stock's liquidity in the market.
Key Highlights
Allotment of 15,54,95,826 new equity shares of face value INR 2 each.
Bonus issue executed in the ratio of 3:1 (3 new shares for every 1 existing share).
Total paid-up share capital increased from previous levels to INR 41,46,55,536.
Post-allotment, the total number of equity shares is 20,73,27,768.
The allotment follows the record date of March 20, 2026, as per SEBI regulations.
👀 What to Watch
Investors should expect the new bonus shares to be credited to their demat accounts shortly; no manual action is required. While the number of shares held increases, the stock price has already adjusted proportionally, making the overall investment value neutral.
Metropolis Healthcare Sets March 20 as Record Date for 3:1 Bonus Issue
Metropolis Healthcare Limited has finalized March 20, 2026, as the record date for its 3:1 bonus share issuance. Shareholders holding the stock on this date will be eligible to receive three additional fully paid-up equity shares for every one share they currently own. This corporate action follows the board's recommendation in February 2026 and recent shareholder approval. The deemed date for the allotment of these new shares is scheduled for March 23, 2026.
Key Highlights
Bonus issue ratio confirmed at 3:1 (3 new shares for every 1 existing share)
Record date for eligibility fixed as Friday, March 20, 2026
Deemed date of allotment for bonus shares is Monday, March 23, 2026
Face value of shares remains unchanged at INR 2 per equity share
👀 What to Watch
Existing shareholders should hold their positions through the record date to qualify for the bonus; note that the share price will adjust downward proportionally on the ex-date. Potential investors should monitor the ex-date to understand the impact on liquidity and price per share.
Metropolis Shareholders Approve Bonus Share Issue with 98.36% Majority
Metropolis Healthcare Limited has received shareholder approval for the issuance of bonus shares through a postal ballot process. The resolution was passed with an overwhelming majority, with 98.36% of the total votes cast in favor of the proposal. This corporate action follows the board's recommendation in February 2026 and aims to reward shareholders while potentially increasing the stock's liquidity. The scrutinizer's report confirms that the e-voting process was conducted fairly between February 7 and March 8, 2026.
Key Highlights
Shareholders approved the issuance of Bonus Shares with 4,69,54,514 votes in favor (98.36%).
Only 1.64% of the votes (7,84,503) were cast against the ordinary resolution.
The total number of equity shares as of the January 30, 2026, cut-off date was 5,18,31,942.
The e-voting period concluded on March 8, 2026, with results officially declared on March 9, 2026.
👀 What to Watch
Investors should monitor the company's upcoming announcements for the 'Record Date' to determine eligibility for the bonus shares. The stock price will adjust proportionally on the ex-bonus date to reflect the increased share count.
